Welcome to LookChem.com Sign In|Join Free
  • or

109581-93-3

Post Buying Request

109581-93-3 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
TACROLIMUS 109581-93-3 supplier
Cas No: 109581-93-3
No Data 1 Milligram 100 Metric Ton/Year Nanjing Sunsure Chemical Technology Co., Ltd Contact Supplier
Tacrolimus monohydrate
Cas No: 109581-93-3
No Data 1 Gram 5 Kilogram/Month CHANGZHOU HANGYU PHARMACEUTICAL TECHNOLOGY CO., LTD Contact Supplier
Tacrolimus monohydrate
Cas No: 109581-93-3
USD $ 1.0-1.0 / Gram 1 Gram 100 Kilogram/Month LIDE PHARMACEUTICALS LIMITED Contact Supplier
Tacrolimus monohydrate
Cas No: 109581-93-3
No Data No Data 10 Kilogram/Month TAIZHOU XINGCHENG CHEMPHARM CO.,LTD. Contact Supplier
High quality Tacrolimus ? supplier in China
Cas No: 109581-93-3
No Data No Data No Data Simagchem Corporation Contact Supplier
TACROLIMUSMONOHYDRATE
Cas No: 109581-93-3
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Hangzhou Dayangchem Co., Ltd. Contact Supplier
API NSC-8746/FK506 99% in stock CAS 109581-93-3
Cas No: 109581-93-3
No Data No Data 1000 Metric Ton/Month Crovell Biotech (Hebei) Co., Ltd. Contact Supplier
109581-93-3 C44H69NO12 TACROLIMUS
Cas No: 109581-93-3
No Data 1 Kilogram 100-200 Kilogram/Month HENAN SUNLAKE ENTERPRISE CORPORATION Contact Supplier
Good supply Tacrolimus Monohydrate Manufacture
Cas No: 109581-93-3
No Data 1 Kilogram 500 Kilogram/Month Hangzhou Think Chemical Co. Ltd Contact Supplier
Tacrolimus monohydrate CAS NO.109581-93-3
Cas No: 109581-93-3
No Data 10 Gram Metric Ton/Day Jilin Tely Imp.& Exp.Co., Ltd. Contact Supplier

109581-93-3 Usage

Definition

ChEBI: A hydrate that is the monohydrate form of tacrolimus.

Uses

immune suppressant, antifungal

Biological Activity

Potent calcineurin (protein phosphatase 2B) inhibitor that requires FK 506-binding protein 12 (FKBP12) for activity (IC 50 = 3 nM). Inhibits secretion of IL-1, IL-2 (IC 50 = 1 nM), IL-3, IL-4, IL-6 (IC 50 = 35 nM), GM-CSF, TNF α (IC 50 = 10 nM), IFN γ and Myc from activated T-cells in vitro . Exhibits potent immunosuppressive, neuroprotective and anticonvulsant activity in vivo .
InChI:InChI=1/C44H69NO12.H2O/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7;/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3;1H2/b25-19+,27-21+;/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+;/m0./s1

109581-93-3 Well-known Company Product Price

Brand (Code)Product description CAS number Packaging Price Detail
Sigma (F4679)  FK-506 monohydrate  ≥98% (HPLC) 109581-93-3 F4679-5MG 2,632.50CNY Detail
TCI America (M2258)  Tacrolimus Monohydrate  >80.0%(HPLC) 109581-93-3 50mg 4,990.00CNY Detail
TCI America (M2258)  Tacrolimus Monohydrate  >80.0%(HPLC) 109581-93-3 10mg 1,390.00CNY Detail

109581-93-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name Tacrolimus Monohydrate

1.2 Other means of identification

Product number -
Other names FK-506 monohydrate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:109581-93-3 SDS

109581-93-3Related news

Comparison of anti-atopic dermatitis activities between DHMEQ and TACROLIMUS (cas 109581-93-3) ointments in mouse model without stratum corneum07/31/2019

This study is aimed to further investigate the anti-atopic dermatitis (AD) activities of dehydroxymethylepoxyquinomicin (DHMEQ) ointment and compare its effect with that of tacrolimus ointment based on the previous study that DHMEQ improves AD-like lesions. AD were induced by 2,4-dinitroclilorob...detailed

An open-label, randomized trial indicates that everolimus with TACROLIMUS (cas 109581-93-3) or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients07/30/2019

This is a randomized trial (ATHENA study) in de novo kidney transplant patients to compare everolimus versus mycophenolic acid (MPA) with similar tacrolimus exposure in both groups, or everolimus with concomitant tacrolimus or cyclosporine (CsA), in an unselected population. In this 12-month, mu...detailed

Relationships between concomitant biologic DMARDs and prednisolone administration and blood TACROLIMUS (cas 109581-93-3) exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients07/29/2019

BackgroundThis study aimed to evaluate the relationships between concomitant biologic disease-modifying anti-rheumatic drugs (DMARDs) and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis (RA) patients without severe disease activity.detailed

Recipient ABCB1, donor and recipient CYP3A5 genotypes influence TACROLIMUS (cas 109581-93-3) pharmacokinetics in liver transplant cases07/28/2019

BackgroundEffective immunosuppression through optimization of trough levels tacrolimus reduces post-transplant mortality rate in liver transplant cases.detailed

Inhibitory effect of immunosuppressive drug TACROLIMUS (cas 109581-93-3) on voltage-gated K+ current in rabbit coronary arterial smooth muscle cells07/27/2019

In the present study, we investigated the inhibitory effect of tacrolimus, a macrolide immunosuppressive drug that acts through calcineurin inhibition, on voltage-gated K+ (Kv) channels expressed in native smooth muscle cells isolated from the coronary arteries of rabbits. Tacrolimus reduced the...detailed

Effectiveness and safety of TACROLIMUS (cas 109581-93-3) therapy for myasthenia gravis: A single arm meta-analysis07/26/2019

To evaluate the effectiveness and safety of tacrolimus in myasthenia gravis (MG) patients, a systematic review and meta-analysis was performed. Researches published between January 1, 2000 and December 31, 2017 in English language were searched in Medline, Embase, Cochrane Central Register of Co...detailed

Conversion From Immediate-Release TACROLIMUS (cas 109581-93-3) to Prolonged-Release TACROLIMUS (cas 109581-93-3) in Stable Heart Transplant Patients: A Retrospective Study07/25/2019

BackgroundLifelong adherence with post-transplant immunosuppression is challenging, with nonadherence associated with greater acute rejection (AR) risk.detailed

Therapeutic drug monitoring of cyclosporine and TACROLIMUS (cas 109581-93-3) in Myanmar kidney transplant patients07/23/2019

IntroductionRenal transplantation is one of the best options for patients suffering from end stage renal disease (ESRD). Cyclosporine and Tacrolimus are mainly applied in immunosuppressive therapy after transplantation of liver, kidney, heart, and other organs. The used of immunosuppressant drug...detailed

TACROLIMUS (cas 109581-93-3) ointment in the management of atopic keratoconjunctivitis07/22/2019

SummaryIntroductionAtopic keratoconjunctivitis is frequently associated with atopic eyelid dermatitis. It may require topical steroids, the prolonged use of which may cause ocular complications. Tacrolimus is an immunosuppressant used topically on the skin in atopic dermatitis. The purpose of th...detailed

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields